Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

被引:0
作者
S M A Kazmi
R M Saliba
M Donato
M Wang
C Hosing
S Qureshi
P Anderlini
U Popat
R E Champlin
S A Giralt
M H Qazilbash
机构
[1] University of Texas Health Science Center at Houston,Department of Internal Medicine
[2] University of Texas MD Anderson Cancer Center,Department of Stem Cell Transplantation and Cellular Therapy
[3] University of Texas MD Anderson Cancer Center,Department of Lymphoma and Myeloma
来源
Bone Marrow Transplantation | 2011年 / 46卷
关键词
topotecan; melphalan; CY; multiple myeloma; autologous stem cell transplant;
D O I
暂无
中图分类号
学科分类号
摘要
In spite of high-dose chemotherapy followed by autologous hematopoietic SCT multiple myeloma (MM) eventually recurs, highlighting the need for more effective treatment approaches. Patients received topotecan 3.5 mg/m2 intravenously on days –6 to –2, melphalan 70 mg/m2 intravenously on days –3 and –2 and CY 1 g/m2 intravenously on days –6, –5 and –4. Overall response rate (ORR) consisting of complete response and partial response (CR+PR, PFS, OS and toxicity are reported. Between August 2002 to March 2004, 60 patients (34 men and 26 women) with a median age of 61 years (range 45–72) were enrolled. Forty-one patients were treated for consolidation of first remission, while 19 patients had relapsed/refractory disease. ORR was 85% (CR 12%, very good PR 43% and PR 30%). Median time to neutrophil (ANC>0.5 × 109/L) and plt engraftment (>20 × 109/L) was 10 (range 7–12 days) and 9 days (range 6–79 days), respectively. A majority of the common adverse events were grade 1–3 mucositis/stomatitis (65%), grade 1 or 2 nausea (59%) and grade 1 or 2 diarrhea (41%). Median PFS was 18.5 months and median OS has yet not been reached. In conclusion, topotecan, melphalan and CY is a safe and active conditioning regimen for auto hematopoietic SCT in MM. The ORR and PFS were comparable to high-dose melphalan.
引用
收藏
页码:510 / 515
页数:5
相关论文
共 50 条
[21]   High-dose melphalan in patients with multiple myeloma [J].
Moreau, P ;
Le Bonniec, M ;
Harousseau, JL .
BULLETIN DU CANCER, 1999, 86 (03) :283-288
[22]   Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation [J].
Samo Zver ;
Vesna Zadnik ;
Peter Černelč ;
Mirta Koželj .
International Journal of Hematology, 2008, 88 :227-236
[23]   Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation [J].
Zver, Samo ;
Zadnik, Vesna ;
Cernelc, Peter ;
Kozelj, Mitra .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) :227-236
[24]   Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study [J].
Thomas Bechtel ;
Ali McBride ;
Brooke Crawford ;
Susan Bullington ;
Craig C. Hofmeister ;
Don M. Benson ;
Samantha Jaglowski ;
Sam Penza ;
Leslie A. Andritsos ;
Steven M. Devine .
Supportive Care in Cancer, 2014, 22 :2911-2916
[25]   Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study [J].
Bechtel, Thomas ;
McBride, Ali ;
Crawford, Brooke ;
Bullington, Susan ;
Hofmeister, Craig C. ;
Benson, Don M., Jr. ;
Jaglowski, Samantha ;
Penza, Sam ;
Andritsos, Leslie A. ;
Devine, Steven M. .
SUPPORTIVE CARE IN CANCER, 2014, 22 (11) :2911-2916
[26]   Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma [J].
Weaver, CH ;
Zhen, B ;
Schwartzberg, LS ;
Leff, R ;
Magee, M ;
Geier, L ;
Deaton, K ;
Lewkow, L ;
Buckner, CD .
BONE MARROW TRANSPLANTATION, 1998, 22 (03) :245-251
[27]   Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015) [J].
Mihee Kim ;
Je-Jung Lee ;
Chang-Ki Min ;
Ji Yun Lee ;
Jae-Cheol Jo ;
Sung-Soo Yoon ;
Sung-Nam Lim ;
Young Rok Do ;
Kihyun Kim ;
Jae Hoon Lee ;
Kwai Han Yoo ;
Sung Hwa Bae ;
Jun Ho Yi ;
Jongheon Jung ;
Hyeon-Seok Eom ;
Sung-Hoon Jung .
Annals of Hematology, 2023, 102 :2233-2240
[28]   Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015) [J].
Kim, Mihee ;
Lee, Je-Jung ;
Min, Chang-Ki ;
Lee, Ji Yun ;
Jo, Jae-Cheol ;
Yoon, Sung-Soo ;
Lim, Sung-Nam ;
Do, Young Rok ;
Kim, Kihyun ;
Lee, Jae Hoon ;
Yoo, Kwai Han ;
Bae, Sung Hwa ;
Yi, Jun Ho ;
Jung, Jongheon ;
Eom, Hyeon-Seok ;
Jung, Sung-Hoon .
ANNALS OF HEMATOLOGY, 2023, 102 (08) :2233-2240
[29]   High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma [J].
Sivaraj, D. ;
Bacon, W. ;
Long, G. D. ;
Rizzieri, D. A. ;
Horwitz, M. E. ;
Sullivan, K. M. ;
Kang, Y. ;
Li, Z. ;
Chao, N. J. ;
Gasparetto, C. .
BONE MARROW TRANSPLANTATION, 2018, 53 (01) :34-38
[30]   A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma [J].
Biran, Noa ;
Rowley, Scott D. ;
Vesole, David H. ;
Zhang, Shijia ;
Donato, Michele L. ;
Richter, Joshua ;
Skarbnik, Alan P. ;
Pecora, Andrew ;
Siegel, David S. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (12) :2165-2171